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Abstract
Introduction Midazolam is used routinely to sedate patients in the intensive care unit (ICU). We
suspected that midazolam over-sedation was occurring in the ICU of the Guy's and St. Thomas' Trust
and that it could be difficult to differentiate this from underlying neurological damage. A sensitive assay
for detecting midazolam and 1-hydroxymidazolam glucuronide (1-OHMG) in serum was developed and
applied in the clinical setting.
Methods In the present study we evaluated a series of cases managed in a mixed medical, surgical
and trauma ICU. Serum was collected from 26 patients who received midazolam, were 'slow to wake'
and in whom there was suspicion of neurological damage. Patient outcome was followed in terms of
mortality, neurological recovery and neurological damage on discharge.
Results Out of 26 patients, 13 had detectable serum levels of midazolam and/or 1-OHMG after a
median of 67 hours (range 36–146 hours) from midazolam cessation. Of these 13 patients in whom
midazolam/1-OHMG was detectable, 10 made a full neurological recovery. Of the remaining 13
patients with no detectable midazolam/1-OHMG, three made a full neurological recovery; 10 patients
were subsequently found to have suffered neurological damage (P < 0.002), eight of whom died and
two were discharged from the ICU with profound neurological damage.
Conclusion These findings confirm that prolonged sedation after midazolam therapy should be
considered in the differential diagnosis of neurological damage in the ICU. This can be reliably detected
by the assay method described. The effects of midazolam/1-OHMG persist days after administration
of midazolam has ceased. After prolonged sedation has been excluded in this patient group, it is highly
likely that neurological damage has occurred.
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Introduction
Midazolam is an intravenous sedative that is commonly used
during ventilation in critical illness. It is often regarded as the
sedative of choice in the intensive care unit (ICU). According
to the findings of our recent electronic survey (93% respond-
ents) [1], midazolam is still routinely used in the UK as a seda-
tive in ICUs.
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R33When used as a single dose, midazolam's pharmacological
characteristics appear favourable, with a rapid onset of action
and a short plasma elimination half-life. Midazolam is 94–98%
bound to plasma albumin and has a volume of distribution of
1.7 l/kg in healthy individuals [2]. It is extensively metabolized
first via cytochromes p450, 3A4 and 2B6 to 1-hydroxymida-
zolam, before undergoing glucuronidation to form 1-hydrox-
ymidazolam glucuronide (1-OHMG), which has sedative
properties and is excreted in the urine [3,4]. A wide interpa-
tient variability in the pharmacokinetic properties of midazolam
in critically ill patients with multiple organ failure has been
reported [5], which can lead to prolonged sedation after mida-
zolam therapy is stopped. However, there are other important
causes of patients being 'slow to wake'; of these, it is most
important to identify severe neurological damage. Patients
with multiple organ failure are at high risk for neurological dam-
age because they frequently have episodes of hypotension
and dysrhythmia, and may have significant coagulopathy dur-
ing the course of their critical illness.
We suspected that some patients in our ICU, particularly
those with renal impairment, were becoming over-sedated
with midazolam and the active metabolite 1-OHMG, and that
this was complicating the neurological assessment of 'slow to
wake' patients. We previously developed a rapid assay for
measuring midazolam and its glucuronide metabolite simulta-
neously [1]. This short report describes the usefulness of this
assay for identifying midazolam over-sedation and its potential
use as a predictor of eventual neurological recovery.
Methods
The assay was available for clinical application in the ICU. To
differentiate between midazolam over-sedation and neurologi-
cal damage, consultant intensivists requested detection of
midazolam and 1-OHMG in serum. This request was normally
made during the morning ICU ward round. The patients stud-
ied were those who had received intravenous midazolam ther-
apy by continuous infusion either before (e.g. in operating
theatres) or during the course of their ICU admission, and who
were 'slow to wake' and in whom there was clinical suspicion
of neurological damage.
Arterial blood (2 ml) was collected from each patient via an in
situ arterial catheter. The time of sample collection and the
midazolam administration history, including cessation time,
were recorded. A specific assay utilizing high-performance liq-
uid chromatography coupled to mass spectrometric detection
was used for simultaneous detection and quantification of
midazolam and 1-OHMG [1]. Mass spectrometry allowed
identification of midazolam and 1-OHMG individually based on
their isotopic patterns. The studies were performed on the
basis of clinical need, and in all cases they were requested by
the consultant intensivist, normally during the morning ward
round. The quantified serum level of midazolam and 1-OHMG
could be reported to the medical team after a minimum of 2
hours so that they could consider the findings in their deci-
sions regarding further clinical intervention. In practice, morn-
ing requests were available for interpretation by the evening
round.
Unit characteristics
The ICU at Guy's and St. Thomas' National Health Service
Trust is a 30-bed, level 3 unit that serves a mixture of medical,
surgical, trauma, oncology and haematology patients. It has an
average of 100 admissions per calendar month. For the year
from March 2003 to April 2004, the mean Acute Physiology
and Chronic Health Evaluation II score (day 1) was 18.5 ± 7.3,
with a hospital mortality of 32.5% and a median length of stay
of 5 days (variance 189.5, maximum 246).
Patient characteristics
All patients appeared to be deeply sedated at the time that the
sample was taken, with a Glasgow Coma Scale score of less
than 5. They were considered 'slow to wake' from either a
pharmacological and neurological cause if, in the absence of
a focal neurological deficit, consciousness did not return
within 36 hours of stopping sedation. Patients were deemed
to have regained consciousness if they both opened their eyes
and moved their limbs in response to commands.
Studies were conducted in 26 patients who had received
midazolam sedation therapy by continuous intravenous infu-
sion and in whom neurological damage was considered clini-
cally possible (e.g. a hypoxic event was noted during cardiac
surgery). The mean age of these patients was 63 ± 16 years,
and the median time from cessation of midazolam therapy to
serum collection was 67 hours (range 36–146 hours). The
median daily midazolam dose was 4 mg/hour (range 2–20 mg/
hour). The reasons for ICU admission are described in Table 1.
We followed the clinical outcomes of these patients in terms
of mortality, neurological recovery and neurological damage
on discharge. If no midazolam or 1-OHMG was detected, then
a series of standard clinical and diagnostic tests was under-
taken to determine whether neurological damage was likely.
These included the response to painful stimuli and computed
tomography of the head. In patients in whom midazolam or 1-
OHMG was detected, tests were deferred until either the
patients awoke or levels became undetectable.
Results
Midazolam and/or 1-OHMG were detected in the serum of 13
of the 26 patients (referred to as the midazolam-positive
group). Of these 13 patients, 10 made a full neurological
recovery; nine of these patients were discharged from the ICU
and one later died as a result of critical illness but with intact
neurological function. The remaining three patients died with-
out regaining consciousness as a result of neurological
damage.
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R34In contrast, neurological damage was observed in 10 of the
remaining 13 patients who had no detectable serum concen-
trations of midazolam and/or 1-OHMG (midazolam-negative
group). Midazolam-positive patients were significantly less
likely to have experienced neurological damage (χ2 test
[degrees of freedom = 1]: P < 0.002).
Twelve of the midazolam-positive patients had serum mida-
zolam concentrations between 16 and 650 ng/ml, with a
median value of 30 ng/ml, whereas the remaining patient's
level exceeded the upper limit of the assay (3000 ng/ml). 1-
OHMG was detected at a mean of 6800 ± 3432 ng/ml (range
3121–11,525 ng/ml) in the serum of six of the 13 midazolam-
positive patients. All six of these patients exhibited a degree of
renal impairment (defined as serum creatinine >130 µmol/l;
Table 1), four of whom required renal replacement therapy in
the form of continuous venovenous haemofiltration (employing
an ultrafiltration rate of between 1500 and 3000 ml/hour). 1-
OHMG was not detected in any of the midazolam-negative
patients.
Of the 13 midazolam-negative patients, eight died without
regaining consciousness as a result of neurological damage,
and two were discharged from the ICU with significant neuro-
logical impairment and required prolonged neurological reha-
bilitation. None of these 10 patients had responded
appropriately to painful stimuli when in the ICU. In addition, in
seven of these patients structural neurological damage was
detected by computed tomography scan. Only three out of 13
patients in this group of midazolam-negative patients left the
ICU with no neurological deficit.
Other sedative and opiate agents
Out of 26 patients, 15 were administered fentanyl by continu-
ous intravenous infusion at a dosage between 0 and 300 µg/
hour. In the 15 patients the fentanyl infusion was ceased at a
minimum of 56 hours and a maximum of 120 hours before
sample collection. In 25 of the 26 patients we could find no
documented evidence of administration of sedative and opiate
agents for a minimum of 36 hours before serum sample collec-
tion. The remaining patient, in the midazolam-negative group,
was receiving 30 mg/day of the sedating antihistamine chlo-
rphenamine; this was one of the three patients who were dis-
charged from the ICU with neurological function intact.
Discussion
In this study, midazolam with or without 1-OHMG was
detected in half of the 'slow to wake' patients, in whom testing
was requested after a mean time from therapy cessation of 3
days. In one patient, in whom there was no record of mida-
zolam administration in the ICU, a level of 200 ng/ml was
recorded. It later transpired that a large dose of midazolam had
been administered in the operating theatre more than 96 hours
earlier. Detection of 1-OHMG in renal impairment confirmed
that 1-OHMG accumulates in the presence of renal failure.
Furthermore, its presence in high serum concentrations
Table 1
Patient characteristics and outcome
Characteristics Midazolam-positive group (n = 13) Midazolam-negative group (n = 13) Statistics
Admission diagnosis
Cardiothoracic surgery 8 6
Severe sepsis 0 4
Cardiorespiratory arrest 2 1
General surgery 2 0
Pancreatitis 1 0
Acute asthma 0 1
Perforated duodenal ulcer 0 1
APACHE II score (day 1; mean ± standard deviation) 19.1 ± 6.6 19.4 ± 7.1
Renal Impairment (serum creatinine >130 µmol/l or 
receiving renal replacement therapy)
5 4
Neurological function intact 10 3 P < 0.002a
Neurological damage 3 10 P < 0.002a
All-cause mortality 4 (31%) 8 (62%)
Median midazolam dose mg/hour (range; 24 hours 
before cessation)
4 (2–20) 3.5 (2–15) NSb
Median time (range) from midazolam cessation (hrs) 66 (36–120) 68 (36–146) NSb
aχ2 test. bMann–Whitney U-test. APACHE, Acute Physiology and Chronic Health Evaluation.
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R35(3121–11,525 ng/ml) in the face of midazolam levels below
the therapeutic range, normally quoted in the critically ill of
100–1000 ng/ml [5], while the patient remained deeply
sedated concurs with earlier reports [3,4] that 1-OHMG has a
sedative effect and contributes to prolonged sedation in renal
impairment. Other investigators have reported the presence of
1-OHMG in the absence of midazolam [3,4], but we did not
observe this and suspect that it was because the assay we
used is able to detect very low concentrations of midazolam.
Our findings suggest that serum levels of midazolam and/or 1-
OHMG in 'slow to wake' patients may be used to aid differen-
tiation between prolonged sedation and neurological damage.
Patients found to be midazolam positive using this rapid assay
were significantly less likely to have suffered neurological dam-
age. Correct discrimination between neurological damage and
prolonged sedation was made for 20 out of 26 patients, indi-
cating a high degree of accuracy. Clearly, the possibility that
midazolam-positive patients also have neurological damage
remains and must be excluded if these patients do not awaken
when serum concentrations of benzodiadepines have fallen to
undetectable levels. Additionally, in the midazolam-negative
group three patients were discharged with neurological func-
tion intact. This of course does not exclude a neurological
cause of the coma that had fully resolved on discharge. One
patient was receiving the sedating antihistamine chlorphen-
amine (30 mg/day intravenously) and did not regain full con-
sciousness until it was stopped. In the remaining two patients
no other clinical cause of the coma was apparent.
The only other agent used routinely in these patients that could
have significantly contributed to their reduced level of con-
sciousness was the intravenous opiate fentanyl. Although fen-
tanyl is known to accumulate in critical illness [6], we could
find no evidence of accumulation for longer than 36 hours [7],
and, because our group of patients had not received the drug
for more than 2 days before sampling, it was not thought to
contribute to the patients being 'slow to wake'.
Arguably, the most important finding is that over three-quarters
of the 'slow to wake' patients with no detectable serum mida-
zolam/1-OHMG either died or were discharged from the ICU
with profound neurological damage, whereas more than three-
quarters of those with detectable midazolam/1-OHMG went
on to make a full recovery. This observation suggests that pro-
longed sedation occurs after midazolam therapy and that it
can be difficult to differentiate this from neurological damage
in the acutely ill patient. The exclusion of midazolam or its
metabolite 1-OHMG should be confirmed either by assay
detection, as we describe, or by using the short-acting benzo-
diazepine antagonist flumazenil before a formal diagnosis of
neurological damage is made. There are reports [3,8] in the lit-
erature of successful reversal of benzodiazepine sedation in
critical illness using flumazenil, but we rarely use it in our unit
because we find it to be nonspecific, short acting and able to
induce seizures [9].
We recommend that use of alternatives to midazolam be con-
sidered in this patient group whenever possible, and that if its
use is considered essential then steps should be taken to
exclude the continuing presence of the drug or its metabolite
before an opinion regarding neurological damage is formed.
These findings have led to a change in prescribing practice in
our ICU. We no longer use midazolam for sedation, and our
sedation policy is now based on administering propofol or
lorazepam. This view is also supported by the Society of Criti-
cal Care Medicine's most recently published guidelines [10],
which recommend use of lorazepam for sedating most
patients via intermittent or continuous infusion and use of pro-
pofol for short-term sedation, and that midazolam be reserved
for rapid control of agitated patients and for short-term seda-
tion. As a consequence, we were unable to conduct a more
formal study of midazolam's role in over-sedation or extend the
study to a larger group of patients.
Conclusion
The results of this investigation confirm that prolonged seda-
tion from midazolam or 1-OHMG should always be considered
in the differential diagnosis of neurological damage in critically
ill patients who have received midazolam. This can be accu-
rately detected using the assay method described. The seda-
tive effects of midazolam/1-OHMG can persist for days after
stopping administration of midazolam. If prolonged sedation
can be excluded in these patients, then it is highly likely that
neurological damage has occurred.
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Key messages
• In some patients midazolam is metabolized to its glu-
curonide, which has sedative properties.
• Prolonged sedation resulting from this metabolite 
should be considered when making a differential diag-
nosis of neurological damage in 'slow to wake' patients.
• Measurement of midzolam and its metabolite in slow to 
wake patients will aid the differential diagnosis in these 
patients.
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